Literature DB >> 32656891

Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.

Ying Zhou1, Ziqing Ye1, Junping Lu1, Shijian Miao1, Xiaolan Lu1, Hua Sun1, Jie Wu1, Yuhuan Wang1, Ying Huang1.   

Abstract

BACKGROUND: Penicillin-allergic children who are infected with Helicobacter pylori constitute a relatively common subgroup. We aimed to study the short-term and long-term effects of bismuth quadruple therapy on gut microbiota in penicillin-allergic children.
METHODS: We prospectively recruited treatment-naive children with H pylori infection and H pylori-negative asymptomatic children as healthy controls. Patients received 14-day bismuth quadruple therapy consisting of omeprazole, clarithromycin, metronidazole, and bismuth. Fecal samples were collected at weeks 0, 2, 6, and 52. Alterations in the gut microbiota were analyzed by 16S rRNA gene sequencing.
RESULTS: Twenty-two subjects (14 gastritis patients, 8 duodenal ulcer patients) and 23 controls participated in this study. At week 2, alpha diversity was reduced in both gastritis (P < .05) and ulcer (except P = .16 with Chao 1 index) patients compared with baseline. Some changes persisted at week 6, and all were restored at week 52. Beta diversity was significantly altered 2 weeks after treatment in the gastritis and duodenal ulcer groups (P = .001, P = .002, respectively) and restored at weeks 6 and 52. The mean relative abundance of Bacteroidetes (P < .001, P = .005, respectively) decreased and that of Proteobacteria increased (P < .001, P = .03, respectively). All alterations recovered at week 6 and 52. In both the gastritis and ulcer groups at week 2, some beneficial bacteria were decreased including Bacteroides (P < .001 and P = .003), Faecalibacterium (P < .001 and P = .02), Phascolarctobacterium (P = .002 and P = .004), Roseburia ( P < .001 and P = .13), Bifidobacterium (P = .08 and P = .04), and Blautia (P < .001 and P = .002). Some detrimental bacteria were increased including Escherichia-Shigella (P < .001 and P = .19), Klebsiella (P < .001, and P = .09), Enterococcus (P < .001 and P = .007), and Streptococcus (P = .002 and P = .004). The changes returned to almost the pre-eradication level 1 year after therapy.
CONCLUSION: Bismuth quadruple therapy causes short-term dysbiosis of the gut microbiota. Most changes recovered 1-year post-eradication, indicating the long-term safety of H pylori therapy.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Helicobacter pylorizzm321990; 16S rRNA sequencing; bismuth quadruple therapy; children; gut microbiota; penicillin allergy

Mesh:

Substances:

Year:  2020        PMID: 32656891     DOI: 10.1111/hel.12721

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  4 in total

1.  The Efficacy of Washed Microbiota Transplantation on Helicobacter pylori Eradication: A Pilot Study.

Authors:  Zhi-Ning Ye; Harry Hua-Xiang Xia; Ran Zhang; Lan Li; Li-Hao Wu; Xu-Juan Liu; Wen-Rui Xie; Xing-Xiang He
Journal:  Gastroenterol Res Pract       Date:  2020-10-19       Impact factor: 2.260

Review 2.  The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management.

Authors:  Ali Nabavi-Rad; Amir Sadeghi; Hamid Asadzadeh Aghdaei; Abbas Yadegar; Sinéad Marian Smith; Mohammad Reza Zali
Journal:  Gut Microbes       Date:  2022 Jan-Dec

3.  Metagenomic Changes of Gut Microbiota following Treatment of Helicobacter pylori Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or Lactobacillus reuteri.

Authors:  Maria Pina Dore; Rosangela Sau; Caterina Niolu; Marcello Abbondio; Alessandro Tanca; Stefano Bibbò; Mariafrancesca Loria; Giovanni Mario Pes; Sergio Uzzau
Journal:  Nutrients       Date:  2022-07-06       Impact factor: 6.706

Review 4.  The interplay between Helicobacter pylori and gastrointestinal microbiota.

Authors:  Chieh-Chang Chen; Jyh-Ming Liou; Yi-Chia Lee; Tzu-Chan Hong; Emad M El-Omar; Ming-Shiang Wu
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.